PMID- 3922982
OWN - NLM
STAT- MEDLINE
DCOM- 19850709
LR  - 20210210
IS  - 0021-9258 (Print)
IS  - 0021-9258 (Linking)
VI  - 260
IP  - 11
DP  - 1985 Jun 10
TI  - Lipoxygenase products of arachidonic acid modulate biosynthesis of 
      platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) by 
      human neutrophils via phospholipase A2.
PG  - 6899-906
AB  - When human neutrophils, previously labeled in their phospholipids with 
      [14C]arachidonate, were stimulated with the Ca2+-ionophore, A23187, plus Ca2+ in 
      the presence of [3H]acetate, these cells released [14C]arachidonate from membrane 
      phospholipids, produced 5-hydroxy-6,8,11,14-[14C]eicosatetraenoic acid (5-HETE) 
      and 14C-labeled 5S,12R-dihydroxy-6-cis,8,10-trans, 14-cis-eicosatetraenoic acid 
      ([14C]leukotriene B4), and incorporated [3H]acetate into platelet-activating 
      factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine). Ionophore 
      A23187-induced formation of these radiolabeled products was greatly augmented by 
      submicromolar concentrations of exogenous 
      5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE), 5-HETE, and leukotriene 
      B4. In the absence of ionophore A23187, these arachidonic acid metabolites were 
      virtually ineffective. Nordihydroguaiaretic acid (NDGA) and several other 
      lipoxygenase/cyclooxygenase inhibitors (butylated hydroxyanisole, 
      3-amino-1-(3-trifluoromethylphenyl)-2-pyrazoline and 1-phenyl-2-pyrazolidinone) 
      caused parallel inhibition of [14C]arachidonate release and [3H]PAF formation in 
      a dose-dependent manner. Specific cyclooxygenase inhibitors, such as indomethacin 
      and naproxen, did not inhibit but rather slightly augmented the formation of 
      these products. Furthermore, addition of 5-HPETE, 5-HETE, or leukotriene B4 (but 
      not 8-HETE or 15-HETE) to neutrophils caused substantial relief of NDGA 
      inhibition of [3H]PAF formation and [14C]arachidonate release. As opposed to 
      [3H]acetate incorporation into PAF, [3H]lyso-PAF incorporation into PAF by 
      activated neutrophils was little affected by NDGA. In addition, NDGA had no 
      effect on lyso-PAF:acetyl-CoA acetyltransferase as measured in neutrophil 
      homogenate preparations. It is concluded that in activated human neutrophils 
      5-lipoxygenase products can modulate PAF formation by enhancing the expression of 
      phospholipase A2.
FAU - Billah, M M
AU  - Billah MM
FAU - Bryant, R W
AU  - Bryant RW
FAU - Siegel, M I
AU  - Siegel MI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Biol Chem
JT  - The Journal of biological chemistry
JID - 2985121R
RN  - 0 (Acetates)
RN  - 0 (Arachidonic Acids)
RN  - 0 (Catechols)
RN  - 0 (Hydroxyeicosatetraenoic Acids)
RN  - 0 (Membrane Lipids)
RN  - 0 (Platelet Activating Factor)
RN  - 214IZI85K3 (Trifluoperazine)
RN  - 27YG812J1I (Arachidonic Acid)
RN  - 37H9VM9WZL (Calcimycin)
RN  - 467RNW8T91 (5-hydroxy-6,8,11,14-eicosatetraenoic acid)
RN  - 7BO8G1BYQU (Masoprocol)
RN  - EC 1.13.11.- (Arachidonate Lipoxygenases)
RN  - EC 1.13.11.12 (Lipoxygenase)
RN  - EC 3.1.- (Phospholipases)
RN  - EC 3.1.1.32 (Phospholipases A)
RN  - EC 3.1.1.4 (Phospholipases A2)
RN  - Q40Q9N063P (Acetic Acid)
SB  - IM
MH  - Acetates/metabolism
MH  - Acetic Acid
MH  - Arachidonate Lipoxygenases
MH  - Arachidonic Acid
MH  - Arachidonic Acids/*metabolism
MH  - Calcimycin/pharmacology
MH  - Catechols/pharmacology
MH  - Humans
MH  - Hydroxyeicosatetraenoic Acids/metabolism
MH  - Lipoxygenase/*metabolism
MH  - Masoprocol
MH  - Membrane Lipids/metabolism
MH  - Neutrophils/*metabolism
MH  - Phospholipases/*metabolism
MH  - Phospholipases A/*metabolism
MH  - Phospholipases A2
MH  - Platelet Activating Factor/*biosynthesis
MH  - Trifluoperazine/pharmacology
EDAT- 1985/06/10 00:00
MHDA- 1985/06/10 00:01
CRDT- 1985/06/10 00:00
PHST- 1985/06/10 00:00 [pubmed]
PHST- 1985/06/10 00:01 [medline]
PHST- 1985/06/10 00:00 [entrez]
AID - S0021-9258(18)88865-2 [pii]
PST - ppublish
SO  - J Biol Chem. 1985 Jun 10;260(11):6899-906.